COMPARISON OF EFFICACY AND SIDE EFFECTS OF SECONDLINE DASATINIB AND NILOTINIB THERAPIES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE RESISTANT OR INTOLERANT TO IMATINIB: PB1947

2019 
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []